Victoria

Woman with pink breast cancer ribbon

New therapy trial from Australian researchers nearly doubles breast cancer cure rates

A phase 3 clinical trial from Melbourne’s Peter MacCallum Cancer Center has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved the cure rate for patients with the most common kind of breast cancer. In the present phase 3 trial, 510 patients were randomized to receive chemotherapy with either intravenous nivolumab or placebo. In patients treated with nivolumab plus chemotherapy, rates were statistically significant, nearly double those who received placebo plus chemo: 24.5% versus 13.8%, respectively.

Molecule of the human hormone glucagon

Australian scientists regenerate diabetics’ damaged cells to produce insulin

For many years, research has focused on identifying novel therapies that stimulate beta-cell growth and function to restore insulin production in type 1 diabetics. Now, researchers at the Baker Heart and Diabetes Institute in Melbourne have brought us a step closer to making this a reality, regenerating damaged pancreatic cells so they can produce insulin and functionally respond to blood glucose levels. The novel therapeutic approach has the potential to become the first disease-modifying treatment for type 1 diabetes.

Scroll to Top